Answers are grounded in this paper and cite their sources.
Neuroblastoma (NB) is a pediatric solid tumor originating in the sympathetic nervous system, primarily affecting children under 10 years old. Metastatic, high-risk NB often exhibits elevated PD-L1 expression, which is linked to poor prognosis. In this study, we screened 41 newly synthesized biphenyl small molecules for activity against PD-L1 highly expressed NB cell lines. Compound SF-9-2 demonstrated the strongest inhibition of PD-L1/PD-1 binding, with an IC50 of 24.9 nM. Additionally, SF-9-2 effectively suppressed the viability of the PD-L1-high SK-N-SH cell line at 5.90 μM. SF-9-2 inhibited epithelial-to-mesenchymal transition, migration, invasion, and proliferation of SK-N-SH cells. It also induced apoptosis and cell cycle arrest. Mechanistic studies revealed that PD-L1 promotes SK-N-SH cell growth via the MAPK signaling pathway. This pro-growth effect was blocked by SF-9-2, and the inhibitory action of SF-9-2 could be reversed by an ERK-specific inhibitor. SF-9-2 further restored GSK-3β activity, enhancing PD-L1 degradation through the ubiquitin-proteasome pathway. More importantly, SF-9-2 significantly inhibited tumor growth in the SK-N-SH NOG mouse model (TGI: 69.45% at 40 mg/kg, i.p.) with no evident toxicity. SF-9-2 also acted as an immune checkpoint inhibitor, blocking PD-L1 to restore T cell function. These findings suggest that SF-9-2 inhibits neuroblastoma growth via both nonimmune and immune mechanisms, providing a promising therapeutic approach for NB.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: